Medpace Holdings Inc MEDP reported fourth-quarter monetary outcomes after the market shut on Monday. Right here’s a rundown of the report.
- This autumn Income: $536.6 million, versus estimates of $534.78 million
- This autumn EPS: $3.67, versus estimates of $2.96
Whole income was up 7.7% on a year-over-year foundation. New enterprise awards totaled $529.7 million within the quarter, down 13.8% year-over-year. The corporate ended the interval with a backlog of roughly $2.9 billion, up 3.2% year-over-year.
Medpace generated $190.7 million in money circulation from operations in the course of the quarter. The corporate had money and money equivalents of $669.4 million as of Dec. 31.
Medpace mentioned it repurchased $174.2 million of its widespread inventory in the course of the quarter. The corporate had $134.6 million remaining beneath its buyback at quarter’s finish. Moreover, Medpace’s board authorized a rise of $600 million to the corporate’s buyback program on Feb. 6.
Examine This Out: Lattice Semiconductor Shares Soar After Combined This autumn Outcomes, Robust Q1 Steerage
Outlook: Medpace expects full-year 2025 income to be within the vary of $2.11 billion to $2.21 billion. The corporate sees full-year earnings within the vary of $11.93 per share to $12.69 per share.
Medpace executives will additional focus on the quarter on a name with traders and analysts at 9 a.m. ET Tuesday morning.
MEDP Value Motion: At publication time Monday, Medpace shares had been down 8.33% at $324.97 in after-hours buying and selling, in accordance with Benzinga Professional.
Picture: Shutterstock.
Overview Ranking:
Speculative
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.